Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV000015420 | SCV002799752 | likely pathogenic | MPI-congenital disorder of glycosylation | 2021-07-28 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000015420 | SCV003845108 | likely pathogenic | MPI-congenital disorder of glycosylation | 2023-02-21 | criteria provided, single submitter | clinical testing | Variant summary: MPI c.305C>T (p.Ser102Leu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251468 control chromosomes (gnomAD). c.305C>T has been reported in the literature in at least compound heterozygous individual affected with Congenital Disorder Of Glycosylation Type 1B (Jaeken_1998). These data do not allow any conclusion about variant significance. When the variant was introduced into the mouse ortholog of the MPI gene and expressed in an mpi-null yeast strain, the variant showed 0.6% residual activity (He_2014), indicating loss of function. One ClinVar submitter has assessed the variant since 2014: the variant was classified as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Baylor Genetics | RCV000015420 | SCV004193273 | likely pathogenic | MPI-congenital disorder of glycosylation | 2024-02-12 | criteria provided, single submitter | clinical testing | |
Laboratory of Medical Genetics, |
RCV000015420 | SCV005051867 | pathogenic | MPI-congenital disorder of glycosylation | 2024-02-01 | criteria provided, single submitter | curation | |
OMIM | RCV000015420 | SCV000035683 | pathogenic | MPI-congenital disorder of glycosylation | 1998-06-01 | no assertion criteria provided | literature only |